SQZ logo

SQZ Biotechnologies (SQZ) Cash From Operations

Annual CFO

-$83.55 M
-$1.41 M-1.72%

December 31, 2022


Summary


Performance

SQZ Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

Earnings dates

OtherSQZcash flowmetrics:

Quarterly CFO

-$23.77 M
-$3.01 M-14.51%

March 31, 2023


Summary


Performance

SQZ Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

Earnings dates

OtherSQZcash flowmetrics:

TTM CFO

-$86.89 M
-$3.34 M-4.00%

March 31, 2023


Summary


Performance

SQZ TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

Earnings dates

OtherSQZcash flowmetrics:

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

SQZ Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-1.7%-16.3%-6.0%
3 y3 years-149.5%-867.8%-2906.4%
5 y5 years-496.0%--

SQZ Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year+1.7%at low+16.3%at low+6.0%at low
5 y5-year+149.5%at low-867.8%at low-2906.4%at low
alltimeall time-496.0%at low-867.8%at low-2906.4%at low

SQZ Biotechnologies Cash From Operations History

DateAnnualQuarterlyTTM
Mar 2023
-
-$23.77 M(+14.5%)
-$86.89 M(+4.0%)
Dec 2022
-$83.55 M(+1.7%)
-$20.76 M(-5.1%)
-$83.55 M(-0.3%)
Sep 2022
-
-$21.88 M(+6.9%)
-$83.81 M(+1.2%)
Jun 2022
-
-$20.48 M(+0.2%)
-$82.82 M(+1.0%)
Mar 2022
-
-$20.43 M(-2.8%)
-$81.99 M(-0.2%)
Dec 2021
-$82.14 M
-$21.02 M(+0.6%)
-$82.14 M(+2.2%)
Sep 2021
-
-$20.89 M(+6.4%)
-$80.36 M(+7.9%)
DateAnnualQuarterlyTTM
Jun 2021
-
-$19.64 M(-4.6%)
-$74.50 M(+11.5%)
Mar 2021
-
-$20.58 M(+7.0%)
-$66.83 M(+54.9%)
Dec 2020
-$43.15 M(+28.8%)
-$19.24 M(+27.9%)
-$43.15 M(+80.5%)
Sep 2020
-
-$15.04 M(+25.7%)
-$23.91 M(+169.6%)
Jun 2020
-
-$11.97 M(-486.5%)
-$8.87 M(-386.5%)
Mar 2020
-
$3.10 M
$3.10 M
Dec 2019
-$33.49 M(-258.7%)
-
-
Dec 2018
$21.10 M
-
-

FAQ

  • What is SQZ Biotechnologies annual cash flow from operations?
  • What is the all time high annual CFO for SQZ Biotechnologies?
  • What is SQZ Biotechnologies annual CFO year-on-year change?
  • What is SQZ Biotechnologies quarterly cash flow from operations?
  • What is the all time high quarterly CFO for SQZ Biotechnologies?
  • What is SQZ Biotechnologies quarterly CFO year-on-year change?
  • What is SQZ Biotechnologies TTM cash flow from operations?
  • What is the all time high TTM CFO for SQZ Biotechnologies?
  • What is SQZ Biotechnologies TTM CFO year-on-year change?

What is SQZ Biotechnologies annual cash flow from operations?

The current annual CFO of SQZ is -$83.55 M

What is the all time high annual CFO for SQZ Biotechnologies?

SQZ Biotechnologies all-time high annual cash flow from operations is $21.10 M

What is SQZ Biotechnologies annual CFO year-on-year change?

Over the past year, SQZ annual cash flow from operations has changed by -$1.41 M (-1.72%)

What is SQZ Biotechnologies quarterly cash flow from operations?

The current quarterly CFO of SQZ is -$23.77 M

What is the all time high quarterly CFO for SQZ Biotechnologies?

SQZ Biotechnologies all-time high quarterly cash flow from operations is $3.10 M

What is SQZ Biotechnologies quarterly CFO year-on-year change?

Over the past year, SQZ quarterly cash flow from operations has changed by -$3.34 M (-16.34%)

What is SQZ Biotechnologies TTM cash flow from operations?

The current TTM CFO of SQZ is -$86.89 M

What is the all time high TTM CFO for SQZ Biotechnologies?

SQZ Biotechnologies all-time high TTM cash flow from operations is $3.10 M

What is SQZ Biotechnologies TTM CFO year-on-year change?

Over the past year, SQZ TTM cash flow from operations has changed by -$4.90 M (-5.98%)